atl1103 development update, page-63

Rob

You obviously have no idea about how biotech licensing with pharma works.

It is the common 'exit strategy' (for a payout) of Biotech companies to partner the big Pharma at Phase 2a, even though the recent Biogen deal on SMA was at Phase 1 stage.

Phase 2a is the stage where licensing deals are make to progress to Phase 2b (18 months trial). Normally Phase 2b and Phase 3 are where big pharmas would be involved.

It has nothing to do with interim results or final results.
Interim just mean there are other results that required more detailed analysis such as the Cancer marker.

You also have to realise that we are talking of a drug development that potentially worth $500million a year. With the shorter timeframe being an orphan drug, it is not like the other drugs.

You may also need to know that the TEVA licensing deal on ATL1102 was DURING the Phase 2a trial, before the Phase 2a results were out.

Hope that helps